{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T15:21:46Z","timestamp":1781796106211,"version":"3.54.5"},"reference-count":31,"publisher":"Japanese Society of Internal Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,3,15]]},"DOI":"10.2169\/internalmedicine.3740-24","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T22:10:48Z","timestamp":1724796648000},"page":"817-823","source":"Crossref","is-referenced-by-count":3,"title":["Nilotinib-induced Diabetes in Japanese Patients with Chronic Myeloid Leukemia"],"prefix":"10.2169","volume":"64","author":[{"given":"Yuichiro","family":"Iwamoto","sequence":"first","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Sanada","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Fushimi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukino","family":"Katakura","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Shimoda","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinori","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Nakanishi","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoatsu","family":"Mune","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Kaku","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Wada","sequence":"additional","affiliation":[{"name":"Department of Hematology, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kaneto","sequence":"additional","affiliation":[{"name":"Department of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Ciftciler R, Haznedaroglu IC. Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence. Eur Rev Med Pharmacol Sci 25: 7787-7798, 2021."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Hartmann JT, Haap M, Kopp HG, Lipp HP. Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 10: 470-481, 2009.","DOI":"10.2174\/138920009788897975"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Ismail AS, Yassin MA. Nilotinib-induced diabetes mellitus in a young female with chronic myeloid leukemia. Cureus 12: e10277, 2020.","DOI":"10.7759\/cureus.10277"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Nakamae H, Yamamoto M, Sakaida E, et al. Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year follow-up of the Japanese subgroup of the randomized ENESTnd trial. Int J Hematol 115: 33-42, 2022.","DOI":"10.1007\/s12185-021-03216-5"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Franklin M, Burns L, Perez S, Yerragolam D, Makenbaeva D. Incidence of type 2 diabetes mellitus and hyperlipidemia in patients prescribed dasatinib or nilotinib as first- or second-line therapy for chronic myelogenous leukemia in the US. Curr Med Res Opin 34: 353-360, 2018.","DOI":"10.1080\/03007995.2017.1399870"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. le Coutre P, Giles FJ, Hochhaus A, et al. Analysis of glucose profiles in imatinib-resistant or intolerant chronic myelogenous leukemia (CML) patients (pts) treated with nilotinib: lack of correlation between glucose levels and nilotinib efficacy. Blood 110: 4588, 2007.","DOI":"10.1182\/blood.V110.11.4588.4588"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Breccia M, Efficace F, Sica S, et al. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leuk Res 39: 1055-1059, 2015.","DOI":"10.1016\/j.leukres.2015.07.004"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Minson AG, Cummins K, Fox L, et al. The natural history of vascular and other complications in patients treated with nilotinib for chronic myeloid leukemia. Blood Adv 3: 1084-1091, 2019.","DOI":"10.1182\/bloodadvances.2018028035"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362: 2251-2259, 2010.","DOI":"10.1056\/NEJMoa0912614"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Rea D, Mirault T, Cluzeau T, et al. Early onset hypercholesterolemia induced by the 2nd-generation tyrosine kinase inhibitor nilotinib in patients with chronic phase-chronic myeloid leukemia. Haematologica 99: 1197-1203, 2014.","DOI":"10.3324\/haematol.2014.104075"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Breccia M, Molica M, Zacheo I, Serrao A, Alimena G. Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment. Ann Hematol 94: 393-397, 2015.","DOI":"10.1007\/s00277-014-2231-9"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Iurlo A, Orsi E, Cattaneo D, et al. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem? Oncotarget 6: 33944-33951, 2015.","DOI":"10.18632\/oncotarget.5580"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Rattanathammethee T, Tantiworawit A, Rattarittamrong E, et al. Peripheral artery occlusive disease among patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors: a cross-sectional case-control study. Clin Med Insights Cardiol 11: 1179546817747258, 2017.","DOI":"10.1177\/1179546817747258"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. do Vale Moreira NC, Ceriello A, Basit A, et al. Race\/ethnicity and challenges for optimal insulin therapy. Diabetes Res Clin Pract 175: 108823, 2021.","DOI":"10.1016\/j.diabres.2021.108823"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Janssen L, Hopman MTE, Swaans GJA, et al. Impact of tyrosine kinase inhibitors on glucose control and insulin regulation in patients with chronic myeloid leukemia. Am J Physiol Endocrinol Metab 324: E209-E216, 2023.","DOI":"10.1152\/ajpendo.00163.2022"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Wu R, Sun JG, Wang JQ, et al. c-Abl inhibition mitigates diet-induced obesity through improving insulin sensitivity of subcutaneous fat in mice. Diabetologia 60: 900-910, 2017.","DOI":"10.1007\/s00125-016-4202-2"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Ito Y, Miyamoto T, Chong Y, Maki T, Akashi K, Kamimura T. Nilotinib exacerbates diabetes mellitus by decreasing secretion of endogenous insulin. Int J Hematol 97: 135-138, 2013.","DOI":"10.1007\/s12185-012-1222-7"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Moslehi JJ, Deininger M. Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33: 4210-4218, 2015.","DOI":"10.1200\/JCO.2015.62.4718"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Iurlo A, Cattaneo D, Bucelli C, Spallarossa P, Passamonti F. Cardiovascular adverse events of tyrosine kinase inhibitors in chronic myeloid leukemia: clinical relevance, impact on outcome, preventive measures and treatment strategies. Curr Treat Options Oncol 24: 1720-1738, 2023.","DOI":"10.1007\/s11864-023-01149-1"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kakadia B, Thakkar R, Sanborn E, Suero-Abreu GA, Jovin TG, Then R. Nilotinib-associated atherosclerosis presenting as multifocal intracranial stenosis and acute stroke. J Stroke Cerebrovasc Dis 30: 105883, 2021.","DOI":"10.1016\/j.jstrokecerebrovasdis.2021.105883"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. G\u00f3mez-Galv\u00e1n JB, Borrego S, Tovar N, Llull L. Nilotinib as a risk factor for ischaemic stroke: a series of three cases. Neurologia (Barcelona, Spain) 32: 411-413, 2017.","DOI":"10.1016\/j.nrleng.2015.11.011"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Aichberger KJ, Herndlhofer S, Schernthaner GH, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol 86: 533-539, 2011.","DOI":"10.1002\/ajh.22037"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Li S, He J, Zhang X, et al. Cardiovascular adverse events in chronic myeloid leukemia patients treated with nilotinib or imatinib: a systematic review, meta-analysis and integrative bioinformatics analysis. Front Cardiovasc Med 9: 966182, 2022.","DOI":"10.3389\/fcvm.2022.966182"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Eddy D, Schlessinger L, Kahn R, Peskin B, Schiebinger R. Relationship of insulin resistance and related metabolic variables to coronary artery disease: a mathematical analysis. Diabetes Care 32: 361-366, 2009.","DOI":"10.2337\/dc08-0854"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Sadiq S, Owen E, Foster T, et al. Nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts. Leukemia 33: 1810-1814, 2019.","DOI":"10.1038\/s41375-018-0337-0"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab 26: 643-656, 2015.","DOI":"10.1016\/j.tem.2015.09.003"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Althubiti M. Tyrosine kinase targeting: a potential therapeutic strategy for diabetes. Saudi J Med Med Sci 10: 183-191, 2022.","DOI":"10.4103\/sjmms.sjmms_492_21"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. H\u00e4gerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioration of diabetes by imatinib mesylate (Gleevec<sup>\u00ae<\/sup>): role of \u03b2-cell NF-\u03baB activation and anti-apoptotic preconditioning. FASEB J 21: 618-628, 2007.","DOI":"10.1096\/fj.06-6910com"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Nat Acad Sci U S A 105: 18895-18900, 2008.","DOI":"10.1073\/pnas.0810246105"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Mokhtari D, Al-Amin A, Turpaev K, et al. Imatinib mesilate-induced phosphatidylinositol 3-kinase signalling and improved survival in insulin-producing cells: role of Src homology 2-containing inositol 5\u2032-phosphatase interaction with c-Abl. Diabetologia 56: 1327-1338, 2013.","DOI":"10.1007\/s00125-013-2868-2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Racil Z, Koritakova E, Sacha T, et al. Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy. Am J Hematol 93: E342-E345, 2018.","DOI":"10.1002\/ajh.25232"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_3740-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T03:31:04Z","timestamp":1742009464000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/6\/64_3740-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.3740-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"article-number":"3740-24"}}